Alzheimer's disease: Seeing the signs early

Journal of the American Academy of Nurse Practitioners

Volumn 21, Issue 11, 2009, Pages 588-595

  Leifer, Bennett P ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Diagnosis; Primary care; Treatment

Indexed keywords

CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; GALANTAMINE; MEMANTINE; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; DISEASE COURSE; HUMAN; PRIMARY HEALTH CARE; PSYCHOMETRY; TIME;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DISEASE PROGRESSION; GALANTAMINE; HUMANS; MEMANTINE; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PHENYLCARBAMATES; PRIMARY HEALTH CARE; PSYCHOMETRICS; TIME FACTORS;

EID: 71049121856     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2009.00436.x     Document Type: Article

References (52)

1. Alzheimer's Association 2006). 10 warning signs of Alzheimer's disease. Retrieved March 10, 2006, from http://www.alz.org/Resources/FactSheets/ 10WarningSi-Eng.pdf.
2. American Psychiatric Association 1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC : American Psychiatric Press.
3. Aronstein, Z., Olsen, R., & Schulman, E. (1996). The nursing assistants use of recreational interventions for behavioral management of residents with Alzheimer's disease. American Journal of Alzheimer's Disease, May/June, 26 31.
4. Birks, J. (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 1 CD005593.
5. Black, S. E., Doody, R., Li, H., McRae, T., Jambor, K. M., Xu, Y., et al. (2007). Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology, 69 (5 459 469.
6. Blake Spangenberg, K. (2006). May 12). Early Alzheimer's versus aging: Noticing the difference. Retrieved May 12, 2006, from http://www.northeastrehab. com/Articles/aging.htm.
7. Borson, S., Scanlan, J., Brush, M., Vitaliano, P., & Dokmak, A. (2000). The mini-cog: A cognitive 'vital signs' measure for dementia screening in multi-lingual elderly. International Journal of Geriatric Psychiatry, 15 (11 1021 1027.
8. Borson, S., Scanlan, J. M., Chen, P., & Ganguli, M. (2003b). The Mini-Cog as a screen for dementia: Validation in a population-based sample. Journal of the American Geriatrics Society, 51 (10 1451 1454.
9. Borson, S., Scanlan, J. M., Chen, P., & Ganguli, M. (2003a). The Mini-Cog as a screen for dementia: Validation in a population-based sample. Journal of the American Geriatrics Society, 51 (10 1451 1454.
10. Boustani, M., Peterson, B., Hanson, L., Harris, R., & Lohr, K. N. (2003). Screening for dementia in primary care: A summary of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 138 (11 927 937.
11. Boxer, A. L., Geschwind, M. D., Belfor, N., Gorno-Tempini, M. L., Schauer, G. F., Miller, B. L., et al. (2006). Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Archives of Neurology, 63 (1 81 86.
12. Buschke, H., Kuslansky, G., Katz, M., Stewart, W. F., Sliwinski, M. J., Eckholdt, H. M., et al. (1999). Screening for dementia with the memory impairment screen. Neurology, 52 (2 231 238.
13. Camicioli, R. & Fisher, N. (2004). Progress in clinical neurosciences: Parkinson's disease with dementia and dementia with Lewy bodies. Canadian Journal of Neurological Science, 31 (1 7 21.
14. Christensen, H. (2001). What cognitive changes can be expected with normal ageing? Australia and New Zealand Journal of Psychiatry, 35 (6 768 775.
15. Cohen-Mansfield, J. (2001a). Nonpharmacologic interventions for inappropriate behaviors in dementia: A review, summary, and critique. American Journal of Geriatric Psychiatry, 9, 361 381.
16. Cohen-Mansfield, J. (2001b). Nonpharmacologic interventions for inappropriate behaviors in dementia: A review, summary, and critique. American Journal of Geriatric Psychiatry, 9, 361 381.
17. Cohen-Mansfield, J. & Werner, P. (1997). Management of verbally disruptive behaviors in nursing home residents. Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 52A (6 M369 M377.
18. Corey-Bloom, J., Anand, R., & Veach, J., for the ENA 713 B352 Study Group (1998). A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology, 1, 55 65.
19. Doody, R. S., Geldmacher, D. S., Gordon, B., Perdomo, C. A., & Pratt, R. D., for the Donepezil Study Group (2001). Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology, 58, 427 433.
20. Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Subbiah, P., Whalen, E., et al. (2001). A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [published erratum appears in Neurology 2001;57(11):2153]. Neurology, 57 (4 613 620.
21. Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., et al. (2005). Global prevalence of dementia: A Delphi consensus study. Lancet, 366 (9503 2112 2117.
22. Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12 (3 189 198.
23. Gauthier, S., Feldman, H., Hecker, J., Vellas, B., Ames, D., Subbiah, P., et al. (2002). Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics, 14 (4 389 404. (Pubitemid 36331605)
24. Geldmacher, D. S., Provenzano, G., McRae, T., Mastey, V., & Ieni, J. R. (2003). Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. Journal of the American Geriatrics Society, 51 (7 937 944.
25. Grossman, H., Bergmann, C., & Parker, S. (2006). Dementia: A brief review. Mount Sinai Journal of Medicine, 73 (7 985 992.
26. Ham, R. (2001). Primary care geriatrics: A case-based approach (4th ed.). St. Louis, MO : Mosby.
27. Harvan, J. R. & Cotter, V. (2006). An evaluation of dementia screening in the primary care setting. Journal of the American Academy of Nurse Practitioners, 18 (8 351 360.
28. Hill, J. W., Futterman, R., Duttagupta, S., Mastey, V., Lloyd, J. R., & Fillit, H. M. (2002). Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare. Neurology, 58, 62 70.
29. Homma, A., Imai, Y., Tago, H., Asada, T., Shigeta, M., Iwamoto, T., et al. (2008). Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: Results from a 24-week, double-blind, placebo-controlled, randomized trial. Dementia and Geriatric Cognitive Disorders, 25 (5 399 407.
30. Jobst, K. A., Barnetson, L. P., & Shepstone, B. J. (1998). Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: The use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging. International Psychogeriatrics, 10 (3 271 302.
31. Karaman, Y., Erdogan, F., Koseoglu, E., Turan, T., & Ersoy, A. O. (2005). A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 19 (1 51 56.
32. Knopman, D., Donohue, J. A., & Gutterman, E. M. (2000). Patterns of care in the early stages of Alzheimer's disease: Impediments to timely diagnosis. Journal of the American Geriatrics Society, 48, 300 304.
33. Kokmen, E., Smith, G. E., Petersen, R. C., Tangalos, E., & Ivnik, R. C. (1991). The short test of mental status. Correlations with standardized psychometric testing. Archives of Neurology, 48 (7 725 728.
34. Lyketsos, C. G., Colenda, C. C., Beck, C., Blank, K., Doraiswamy, M. P., Kalunian, D. A., et al. (2006). Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. American Journal of Geriatric Psychiatry, 14 (7 561 572.
35. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939 944.
36. Namazi, K. H., Gwinnup, P. B., & Zadorozny, C. A. (1994). A low intensity exercise/movement program for patients with Alzheimer's disease: The TEMP-AD protocol. Journal of Aging and Physical Activity, 2, 80 92.
37. National Institute on Aging 2007). Alzheimer's disease fact sheet. Retrieved July 10, 2007, from http://www.nia.nih.gov/Alzheimers/Publications/ adfact.htm.
38. Petersen, R. C., Stevens, J. C., Ganguli, M., Tangalos, E. G., Cummings, J. L., & DeKosky, S. T. (2001). Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 56 (9 1133 1142.
39. Rabins, P. V., Blacker, D., Rovner, B. W., Rummans, T., Schneider, L. S., Tariot, P. N., et al. (2007). American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias (2nd ed). American Journal of Psychiatry, 164 (Suppl. 12 5 56.
40. Rehman, H. U. (2000). Progressive supranuclear palsy. Postgraduate Medical Journal, 76 (896 333 336.
41. Rogers, J. C., Holm, M. B., Burgio, L. D., Granieri, E., Hsu, C., Hardin, J. M., et al. (1999). Improving morning care routines of nursing home residents with dementia. Journal of the American Geriatrics Society, 47 (9 1049 1057.
42. Roman, G. C. (2003). Vascular dementia: Distinguishing characteristics, treatment, and prevention. Journal of the American Geriatrics Society, 51 (5 Suppl. Dementia S296 S304.
43. Sano, M., Amatniek, J., Feely, M., Sinyak, F., Holton, D., Scher, S., et al. (2005). Undertreatment of patients with Alzheimer's disease in an elderly United States population. Alzheimer's & Dementia, 1, 136 144.
44. Seltzer, B., Zolnouni, P., Nunez, M., Goldman, R., Kumar, D., Ieni, J., et al. (2004). Efficacy of donepezil in early-stage Alzheimer disease: A randomized placebo-controlled trial. Archives of Neurology, 61 (12 1852 1856. (Pubitemid 39612945)
45. Solomon, P. R., Hirschoff, A., Kelly, B., Relin, M., Brush, M., DeVeaux, R. D., et al. (1998). A 7-minute neurocognitive screening battery highly sensitive to Alzheimer's disease. Archives of Neurology, 55 (3 349 355.
46. Solomon, P. R. & Murphy, C. A. (2005). Should we screen for Alzheimer's disease? A review of the evidence for and against screening Alzheimer's disease in primary care practice. Geriatrics, 60 (11 26 31.
47. Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., Ding, C., et al. (2000). A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology, 54 (12 2269 2276.
48. Teri, L., Truax, P., Logsdon, R., Uomoto, J., Zarit, S., & Vitaliano, P. P. (1992). Assessment of behavioral problems in dementia: The revised memory and behavior problems checklist. Psychology and Aging, 7 (4 622 631.
49. Trevitt, C. R. & Singh, P. N. (2003). Variant Creutzfeldt-Jakob disease: Pathology, epidemiology, and public health implications. American Journal of Clinical Nutrition, 78 (Suppl. 3 651S 656S.
50. Winblad, B., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., Wimo, A., et al. (2001). A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology, 57 (3 489 495.
51. Winblad, B., Kilander, L., Eriksson, S., Minthon, L., Batsman, S., Wetterholm, A. L., et al. (2006a). Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study. Lancet, 367 (9516 1057 1065.
52. Winblad, B., Kilander, L., Eriksson, S., Minthon, L., Batsman, S., Wetterholm, A. L., et al. (2006b). Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study. Lancet, 367 (9516 1057 1065.